Agilent Technologies, Inc. (A) Price/FCF Ratio: 29.76
Is Agilent Technologies, Inc.’s Price/FCF ratio high or low?
Agilent Technologies, Inc.'s Price/FCF ratio of 29.76 is in line with its 5-year average of 32.17, around the middle of its 5-year range (21.02–46.42).
The Price/FCF ratio for Agilent Technologies, Inc. (A) is 29.76. It is below its 12-month average by 9.83% (33.00).
A Price/FCF Ratio Chart
A Average Price/FCF Ratio Chart
A Current vs Average Price/FCF Ratio Chart
A Price/FCF Ratio Metrics
PRICE/FCF RATIO
29.76
PRICE/FCF RATIO AVG TTM
33.00
PRICE/FCF RATIO AVG 3Y
28.84
PRICE/FCF RATIO AVG 5Y
32.17
PRICE/FCF RATIO AVG 10Y
31.62
PRICE/FCF RATIO AVG 15Y
27.78
PRICE/FCF RATIO AVG 20Y
24.88
CURRENT VS TTM AVG
-9.83%
CURRENT VS 3Y AVG
+3.19%
CURRENT VS 5Y AVG
-7.51%
CURRENT VS 10Y AVG
-5.87%
CURRENT VS 15Y AVG
+7.14%
CURRENT VS 20Y AVG
+19.60%
A Competitors' Price/FCF Ratio
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agilent Technologies, Inc. (A) | $37.17B | 29.76 | 33.00 | 28.84 | 32.17 |
| Zoetis Inc. (ZTS) | $34.20B | 16.13 | 25.54 | 39.28 | 45.60 |
| Centene Corporation (CNC) | $31.94B | 5.05 | 8.66 | 22.84 | 17.16 |
| Medline Inc. (MDLN) | $30.90B | 19.77 | 21.15 | 21.15 | 21.15 |
| IQVIA Holdings Inc. (IQV) | $30.60B | 11.65 | 13.97 | 20.37 | 21.30 |
| Humana Inc. (HUM) | $43.78B | 34.61 | 25.46 | 17.19 | 27.43 |
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 42.11 | 55.32 | 55.81 | 64.50 |
| DexCom, Inc. (DXCM) | $29.24B | 20.82 | 36.11 | 64.02 | 176.73 |
| Biogen Inc. (BIIB) | $29.00B | 11.12 | 11.07 | 18.73 | 18.56 |
| Veeva Systems Inc. (VEEV) | $26.73B | 52.43 | 30.62 | 33.98 | 39.46 |
Free Cash Flow Valuation
P/FCF Ratio
29.8
FCF Yield
3.36%
Agilent Technologies, Inc. Price/FCF Ratio Formula & Definition
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Agilent Technologies, Inc. Price/FCF Ratio FAQ
- What is the Price/FCF ratio for Agilent Technologies, Inc. (A)?
- The Price/FCF ratio for A stock is 29.76.
- Is Agilent Technologies, Inc.'s Price/FCF ratio high or low?
- Agilent Technologies, Inc.'s Price/FCF ratio of 29.76 is in line with its 5-year average of 32.17, around the middle of its 5-year range (21.02–46.42).
- What is the TTM average Price/FCF ratio for Agilent Technologies, Inc. (A)?
- The TTM average Price/FCF ratio for A stock is 33.00.
- What is the 3Y average Price/FCF ratio for Agilent Technologies, Inc. (A)?
- The 3Y average Price/FCF ratio for A stock is 28.84.
- What is the 5Y average Price/FCF ratio for Agilent Technologies, Inc. (A)?
- The 5Y average Price/FCF ratio for A stock is 32.17.
- What is the 10Y average Price/FCF ratio for Agilent Technologies, Inc. (A)?
- The 10Y average Price/FCF ratio for A stock is 31.62.
- What is the 15Y average Price/FCF ratio for Agilent Technologies, Inc. (A)?
- The 15Y average Price/FCF ratio for A stock is 27.78.
- What is the 20Y average Price/FCF ratio for Agilent Technologies, Inc. (A)?
- The 20Y average Price/FCF ratio for A stock is 24.88.
Agilent Technologies, Inc. Price/FCF Ratio History
| DATE | PRICE/FCF RATIO |
|---|---|
| 2026-06-10 | 29.76 |
| 2026-06-09 | 30.63 |
| 2026-06-08 | 30.00 |
| 2026-06-05 | 30.62 |
| 2026-06-04 | 31.29 |
| 2026-06-03 | 31.07 |
| 2026-06-02 | 30.54 |
| 2026-06-01 | 30.75 |
| 2026-05-29 | 38.76 |
| 2026-05-28 | 38.72 |
| 2026-05-27 | 33.13 |
| 2026-05-26 | 32.91 |
| 2026-05-22 | 32.88 |
| 2026-05-21 | 32.83 |
| 2026-05-20 | 32.54 |
| 2026-05-19 | 31.62 |
| 2026-05-18 | 32.06 |
| 2026-05-15 | 31.95 |
| 2026-05-14 | 32.39 |
| 2026-05-13 | 32.24 |
| 2026-05-12 | 32.29 |
| 2026-05-11 | 31.88 |
| 2026-05-08 | 33.07 |
| 2026-05-07 | 33.93 |
| 2026-05-06 | 33.66 |
| 2026-05-05 | 33.61 |
| 2026-05-04 | 32.08 |
| 2026-05-01 | 32.75 |
| 2026-04-30 | 33.05 |
| 2026-04-29 | 31.83 |
| 2026-04-28 | 32.85 |
| 2026-04-27 | 33.07 |
| 2026-04-24 | 33.05 |
| 2026-04-23 | 32.72 |
| 2026-04-22 | 34.45 |
| 2026-04-21 | 34.92 |
| 2026-04-20 | 34.59 |
| 2026-04-17 | 34.86 |
| 2026-04-16 | 33.82 |
| 2026-04-15 | 34.25 |
| 2026-04-14 | 34.43 |
| 2026-04-13 | 33.61 |
| 2026-04-10 | 32.91 |
| 2026-04-09 | 33.00 |
| 2026-04-08 | 33.44 |
| 2026-04-07 | 32.57 |
| 2026-04-06 | 32.84 |
| 2026-04-02 | 33.03 |
| 2026-04-01 | 32.76 |
| 2026-03-31 | 32.60 |
| 2026-03-30 | 32.04 |
| 2026-03-27 | 31.53 |
| 2026-03-26 | 32.46 |
| 2026-03-25 | 32.31 |
| 2026-03-24 | 32.66 |
| 2026-03-23 | 32.04 |
| 2026-03-20 | 31.83 |
| 2026-03-19 | 31.96 |
| 2026-03-18 | 31.89 |
| 2026-03-17 | 32.25 |
| 2026-03-16 | 31.98 |
| 2026-03-13 | 31.89 |
| 2026-03-12 | 31.93 |
| 2026-03-11 | 33.01 |
| 2026-03-10 | 33.01 |
| 2026-03-09 | 33.36 |
| 2026-03-06 | 32.91 |
| 2026-03-05 | 33.78 |
| 2026-03-04 | 34.47 |
| 2026-03-03 | 34.05 |
| 2026-03-02 | 29.13 |
| 2026-02-27 | 29.92 |
| 2026-02-26 | 29.82 |
| 2026-02-25 | 30.75 |
| 2026-02-24 | 30.67 |
| 2026-02-23 | 30.62 |
| 2026-02-20 | 30.30 |
| 2026-02-19 | 31.15 |
| 2026-02-18 | 31.29 |
| 2026-02-17 | 30.54 |
| 2026-02-13 | 31.02 |
| 2026-02-12 | 30.79 |
| 2026-02-11 | 31.78 |
| 2026-02-10 | 31.80 |
| 2026-02-09 | 31.43 |
| 2026-02-06 | 31.95 |
| 2026-02-05 | 31.96 |
| 2026-02-04 | 32.78 |
| 2026-02-03 | 32.58 |
| 2026-02-02 | 33.38 |
| 2026-01-30 | 33.00 |
| 2026-01-29 | 32.85 |
| 2026-01-28 | 33.00 |
| 2026-01-27 | 33.52 |
| 2026-01-26 | 33.44 |
| 2026-01-23 | 33.29 |
| 2026-01-22 | 34.18 |
| 2026-01-21 | 34.46 |
| 2026-01-20 | 33.49 |
| 2026-01-16 | 34.43 |
| 2026-01-15 | 35.70 |
| 2026-01-14 | 35.97 |
| 2026-01-13 | 36.07 |
| 2026-01-12 | 36.48 |
| 2026-01-09 | 36.61 |
| 2026-01-08 | 35.93 |
| 2026-01-07 | 36.44 |
| 2026-01-06 | 36.39 |
| 2026-01-05 | 35.24 |
| 2026-01-02 | 34.01 |
| 2025-12-31 | 33.55 |
| 2025-12-30 | 33.93 |
| 2025-12-29 | 34.00 |
| 2025-12-26 | 34.12 |
| 2025-12-24 | 34.10 |
| 2025-12-23 | 34.11 |
| 2025-12-22 | 34.15 |
| 2025-12-19 | 33.83 |
| 2025-12-18 | 35.86 |
| 2025-12-17 | 35.80 |
| 2025-12-16 | 36.46 |
| 2025-12-15 | 36.83 |
| 2025-12-12 | 36.59 |
| 2025-12-11 | 37.42 |
| 2025-12-10 | 37.58 |
| 2025-12-09 | 36.84 |
| 2025-12-08 | 37.31 |
| 2025-12-05 | 38.11 |
| 2025-12-04 | 38.85 |
| 2025-12-03 | 39.10 |
| 2025-12-02 | 38.98 |
| 2025-12-01 | 39.32 |
| 2025-11-28 | 40.21 |
| 2025-11-26 | 40.44 |
| 2025-11-25 | 41.18 |
| 2025-11-24 | 40.24 |
| 2025-11-21 | 39.62 |
| 2025-11-20 | 38.00 |
| 2025-11-19 | 37.83 |
| 2025-11-18 | 37.68 |
| 2025-11-17 | 37.86 |
| 2025-11-14 | 38.46 |
| 2025-11-13 | 38.48 |
| 2025-11-12 | 39.69 |
| 2025-11-11 | 39.14 |
| 2025-11-10 | 38.34 |
| 2025-11-07 | 38.44 |
| 2025-11-06 | 38.63 |
| 2025-11-05 | 38.45 |
| 2025-11-04 | 38.27 |
| 2025-11-03 | 37.90 |
| 2025-10-31 | 38.34 |
| 2025-10-30 | 37.55 |
| 2025-10-29 | 37.51 |
| 2025-10-28 | 38.21 |
| 2025-10-27 | 38.40 |
| 2025-10-24 | 38.78 |
| 2025-10-23 | 38.63 |
| 2025-10-22 | 38.21 |
| 2025-10-21 | 38.16 |
| 2025-10-20 | 37.46 |
| 2025-10-17 | 37.18 |
| 2025-10-16 | 36.96 |
| 2025-10-15 | 36.58 |
| 2025-10-14 | 36.16 |
| 2025-10-13 | 36.21 |
| 2025-10-10 | 35.79 |
| 2025-10-09 | 36.70 |
| 2025-10-08 | 36.88 |
| 2025-10-07 | 36.30 |
| 2025-10-06 | 37.09 |
| 2025-10-03 | 37.10 |
| 2025-10-02 | 36.33 |
| 2025-10-01 | 36.30 |
| 2025-09-30 | 33.62 |
| 2025-09-29 | 32.42 |
| 2025-09-26 | 32.32 |
| 2025-09-25 | 31.93 |
| 2025-09-24 | 32.58 |
| 2025-09-23 | 32.99 |
| 2025-09-22 | 33.09 |
| 2025-09-19 | 33.09 |
| 2025-09-18 | 33.43 |
| 2025-09-17 | 33.19 |
| 2025-09-16 | 33.32 |
| 2025-09-15 | 32.91 |
| 2025-09-12 | 32.28 |
| 2025-09-11 | 33.20 |
| 2025-09-10 | 32.51 |
| 2025-09-09 | 33.07 |
| 2025-09-08 | 33.56 |
| 2025-09-05 | 33.73 |
| 2025-09-04 | 33.66 |
| 2025-09-03 | 32.80 |
| 2025-09-02 | 32.80 |
| 2025-08-29 | 32.92 |
| 2025-08-28 | 29.95 |
| 2025-08-27 | 28.45 |
| 2025-08-26 | 28.36 |
| 2025-08-25 | 28.56 |
| 2025-08-22 | 29.15 |
| 2025-08-21 | 28.08 |
| 2025-08-20 | 28.55 |
| 2025-08-19 | 28.79 |
| 2025-08-18 | 28.32 |
| 2025-08-15 | 28.57 |
| 2025-08-14 | 28.49 |
| 2025-08-13 | 28.83 |
| 2025-08-12 | 28.12 |
| 2025-08-11 | 27.36 |
| 2025-08-08 | 27.47 |
| 2025-08-07 | 27.32 |
| 2025-08-06 | 27.14 |
| 2025-08-05 | 27.54 |
| 2025-08-04 | 27.53 |
| 2025-08-01 | 27.21 |
| 2025-07-31 | 27.52 |
| 2025-07-30 | 28.30 |
| 2025-07-29 | 28.73 |
| 2025-07-28 | 28.65 |
| 2025-07-25 | 28.81 |
| 2025-07-24 | 28.85 |
| 2025-07-23 | 28.64 |
| 2025-07-22 | 27.85 |
| 2025-07-21 | 26.86 |
| 2025-07-18 | 27.32 |
| 2025-07-17 | 27.89 |
| 2025-07-16 | 27.19 |
| 2025-07-15 | 27.07 |
| 2025-07-14 | 28.78 |
| 2025-07-11 | 29.55 |
| 2025-07-10 | 29.76 |
| 2025-07-09 | 29.08 |
| 2025-07-08 | 29.01 |
| 2025-07-07 | 28.58 |
| 2025-07-03 | 29.09 |
| 2025-07-02 | 28.92 |
| 2025-07-01 | 28.87 |
| 2025-06-30 | 28.29 |
| 2025-06-27 | 28.56 |
| 2025-06-26 | 28.62 |
| 2025-06-25 | 28.43 |
| 2025-06-24 | 28.20 |
| 2025-06-23 | 27.84 |
| 2025-06-20 | 27.70 |
| 2025-06-18 | 27.69 |
| 2025-06-17 | 27.83 |
| 2025-06-16 | 28.53 |
| 2025-06-13 | 28.06 |
| 2025-06-12 | 28.50 |
| 2025-06-11 | 28.70 |
| 2025-06-10 | 28.89 |
| 2025-06-09 | 27.98 |
| 2025-06-06 | 27.76 |
| 2025-06-05 | 27.31 |
| 2025-06-04 | 27.55 |
| 2025-06-03 | 27.03 |
| 2025-06-02 | 26.62 |
| 2025-05-30 | 26.83 |
| 2025-05-29 | 24.78 |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Agilent Technologies, Inc.
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Padraig McDonnell